HomeCompareIIVI vs PFE

IIVI vs PFE: Dividend Comparison 2026

IIVI yields 5.28% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PFE wins by $21.2K in total portfolio value· pulled ahead in Year 9
10 years
IIVI
IIVI
● Live price
5.28%
Share price
$227.08
Annual div
$12.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.3K
Annual income
$740.73
Full IIVI calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — IIVI vs PFE

📍 PFE pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIIVIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IIVI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IIVI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IIVI
Annual income on $10K today (after 15% tax)
$449.18/yr
After 10yr DRIP, annual income (after tax)
$629.62/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, PFE beats the other by $21,690.28/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IIVI + PFE for your $10,000?

IIVI: 50%PFE: 50%
100% PFE50/50100% IIVI
Portfolio after 10yr
$38.9K
Annual income
$13,499.72/yr
Blended yield
34.67%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on IIVI right now

IIVI
Analyst Ratings
19
Buy
5
Hold
1
Sell
Consensus: Buy
Altman Z
0.3
Piotroski
5/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IIVI buys
0
PFE buys
0
No recent congressional trades found for IIVI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIIVIPFE
Forward yield5.28%6.13%
Annual dividend / share$12.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$28.3K$49.6K
Annual income after 10y$740.73$26,258.71
Total dividends collected$6.4K$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: IIVI vs PFE ($10,000, DRIP)

YearIIVI PortfolioIIVI Income/yrPFE PortfolioPFE Income/yrGap
1$11,228$528.45$9,153$693.39+$2.1KIIVI
2$12,569$554.55$8,593$849.25+$4.0KIIVI
3$14,029$580.14$8,336$1,066.78+$5.7KIIVI
4$15,616$605.17$8,437$1,384.80+$7.2KIIVI
5$17,339$629.57$9,013$1,875.40+$8.3KIIVI
6$19,206$653.29$10,306$2,680.72+$8.9KIIVI
7$21,227$676.29$12,820$4,101.38+$8.4KIIVI
8$23,411$698.55$17,673$6,826.70+$5.7KIIVI
9← crossover$25,770$720.03$27,543$12,591.86$1.8KPFE
10$28,314$740.73$49,560$26,258.71$21.2KPFE

IIVI vs PFE: Complete Analysis 2026

IIVIStock

II-VI Incorporated develops, manufactures, and markets engineered materials, optoelectronic components, and devices worldwide. It operates in two segments, Compound Semiconductors and Photonic Solutions. The Compound Semiconductors segment provides optical and electro-optical components and materials used in high-power CO2 lasers, fiber-lasers, and direct diode lasers for materials processing applications; infrared optical components and high-precision optical assemblies for aerospace and defense, medical, and commercial laser imaging applications; semiconductor lasers and detectors for optical interconnects and sensing applications; engineered materials for thermoelectric, ceramics, and silicon carbide various applications; and compound semiconductor epitaxial wafers for applications in optical and wireless communication. The Photonic Solutions segment manufactures transceivers for data centers and telecom optical networks; pump lasers, optical amplifiers, wavelength selective switches, and advanced components for telecom networks; and crystal materials, optics, lasers, and optoelectronic modules in a range of applications, including optical communications, life sciences, and consumer electronics markets. The company serves original equipment manufacturers, laser end users, system integrators of high-power lasers, U.S. government prime contractors, and various U.S. government agencies, as well as manufacturers of equipment and devices for industrial, optical communications, consumer electronics, and security and monitoring applications. The company was incorporated in 1971 and is headquartered in Saxonburg, Pennsylvania.

Full IIVI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this IIVI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IIVI vs SCHDIIVI vs JEPIIIVI vs OIIVI vs KOIIVI vs MAINIIVI vs JNJIIVI vs MRKIIVI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.